EyePoint, Inc. EYPT
0.27 USD -0.02 (-8.08%)
Regular-session close
0.27 0.00 0.00%
After hours · Nov 18, 4:30 PM ET
0.266 Day range 0.3168
0.266 52-week range 19.11
- YTD
- -98.51%
- 1 year
- -98.05%
News
prnewswire.com EYPT Investors Have Opportunity to Lead EyePoint, Inc. Securities Fraud Lawsuit NEW YORK, Nov. 18, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of EyePoint, Inc. (NASDAQ: EYPT)…
businesswire.com Rosen Law Firm Urges EyePoint, Inc. (NASDAQ: EYPT) Stockholders to Contact the Firm for Information About Their Rights NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of EyePoint, Inc. (NASDAQ: EYPT) between May 27,…
globenewswire.com EYPT INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of EyePoint, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm ATLANTA, Nov. 18, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against EyePoint, Inc. (“EyePoint”) (NASDAQ: EYPT). The lawsuit alleges that Defendants made false and…
businesswire.com Investor Alert: Robbins LLP Informs Investors of the EyePoint, Inc. Class Action Lawsuit SAN DIEGO--(BUSINESS WIRE)---- $EYPT #EYPT--EyePoint allegedly misled investors regarding the efficacy and viability of DURAVYU for the treatment of wet age-related macular degeneration.
seekingalpha.com EyePoint, Inc. (EYPT) Presents at UBS Global Biopharma Conference 2026 Transcript EyePoint, Inc. ( EYPT ) UBS Global Biopharma Conference 2026 November 17, 2026 3:40 AM EST Company Participants George Elston - Executive VP & CFO Jay Duker - President, CEO & Director Conference…benzinga.com Stifel Maintains Buy on EyePoint, Lowers Price Target to $5 Stifel analyst Annabel Samimy maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $6 to $5.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Oragenics (AMEX:OGEN) stock increased by 30.2% to $0.46 during Thursday's after-market session. The market value of their outstanding shares is at $1.5 million. InspireMD (NASDAQ:NSPR) shares…
seekingalpha.com EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to…
zacks.com EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates EyePoint (EYPT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.85 per share a year ago.
benzinga.com EyePoint Pharmaceuticals Q3 2026 Earnings Call Transcript EyePoint Pharmaceuticals (NASDAQ:EYPT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com EyePoint Pharmaceuticals Q3 EPS $(1.07) Misses $(0.91) Estimate, Sales $756.000K Beat $223.077K Estimate EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.91) by 17.58 percent. This is a 25.88 percent decrease over…
globenewswire.com EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments – Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the positive Phase 2 VERONA trial and…benzinga.com RBC Capital Maintains Sector Perform on EyePoint, Lowers Price Target to $1 RBC Capital analyst Lisa Walter maintains EyePoint (NASDAQ:EYPT) with a Sector Perform and lowers the price target from $5 to $1.
benzinga.com Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
benzinga.com Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300 points on Monday.The Dow traded up 0.06% to 52,031.59 while the NASDAQ jumped 1.24% to 26,465.39.…
benzinga.com EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus EyePoint cuts 53% of staff and halts wet AMD trials after DURAVYU misses its Phase 3 primary endpoint, pivoting its focus entirely to DME.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX)…
benzinga.com Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views U.S. stocks mixed: Nasdaq +1.09%, S&P 500 +0.54%, Dow -0.12%. Tech led gains; utilities lagged. Oil fell, gold rose; Europe lower.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…benzinga.com Eyepoint Says Topline Results From Lucia Phase 3 Trial Of Duravyu (Vorolanib Intravitreal Insert) For Wet Age-Related Macular Degeneration Did Not Achieve The Primary Endpoint – LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement –– Key secondary…
